ImmuCell (ICCC) vs Milestone Pharmaceuticals (MIST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
ImmuCell (ICCC) has outperformed Milestone Pharmaceuticals (MIST) over the past year, gaining 48.0% versus a loss of 64.4%. Over five years, ICCC leads with a +5.1% price change compared with -87.9% for MIST. Milestone Pharmaceuticals is the larger company by market cap ($88.7 million vs $88.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ICCC | MIST |
|---|---|---|
| Share price | $9.75 | $0.7121 |
| Market cap | $88.55M | $88.66M |
| 1-day change | +0.62% | -5.96% |
| YTD return | +58.54% | -64.75% |
| 1-year return | +47.95% | -64.39% |
| 5-year return | +5.06% | -87.93% |
| P/E ratio (TTM) | 139.29 | — |
| EPS (TTM) | $0.07 | $-0.68 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.10 | $3.06 |
| 52-week low | $4.52 | $0.709 |
| Distance from 52-week high | -19.42% | -76.73% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +722.92% |
| Average volume | 22.20K | 1.40M |
| Shares outstanding | 9.08M | 124.50M |
| Employees | 73 | 38 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ICCC has outperformed MIST by 112.3 percentage points over the past year.
About ImmuCell
ICCC stock →ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis.
Healthcare · Biotechnology · 73 employees
About Milestone Pharmaceuticals
MIST stock →Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Healthcare · Biotechnology · 38 employees
ICCC vs MIST FAQ
Which is bigger, ImmuCell or Milestone Pharmaceuticals?
Milestone Pharmaceuticals (MIST) is larger, with a market capitalization of $88.66M compared with $88.55M for ImmuCell (ICCC).
Which stock has performed better over the past year, ICCC or MIST?
ICCC returned +47.95% over the past 12 months, compared with -64.39% for MIST (price return, excluding dividends). Past performance does not predict future results.
Are ImmuCell and Milestone Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.